01
Liquid biopsy
Circulating tumour DNA and cell-based assays moving from the research bench toward the clinic.
An international meeting · Byers Eye Institute, Stanford
Innovate Ocular Oncology
Rare cancers move fastest where every discipline is in the room. Two days at Stanford put scientific, clinical and industry leaders around the same questions: new approvals, new assays and the patients waiting on both. Faculty and attendees are coming from Mexico, Brazil, the Netherlands, Canada, Switzerland and beyond.
This meeting does not offer CME credit · Supported by an educational grant from Aura Biosciences
01 · Overview
A field changing faster than its textbooks
Innovate Ocular Oncology carries on the Innovate series tradition. It puts scientific, clinical and industry leaders in one room on the state of the art and future trends in ocular oncology, at a moment of new therapy approvals, expanding clinical trials and advanced diagnostics.
The unmet needs are the reason the room exists: treatment burden, toxicities and access to care. Liquid biopsy. Adjuvant and neoadjuvant therapeutics in uveal melanoma. New FDA approvals, intraocular lymphoma, radiation and black-box drug toxicities, plus new directions in retinoblastoma. Hard questions, lively discussion and a collegial interdisciplinary environment.
On the table
- Liquid biopsy
- Uveal melanoma
- Adjuvant therapy
- Neoadjuvant therapy
- FDA approvals
- Intraocular lymphoma
- Radiation toxicities
- Retinoblastoma
- Advanced diagnostics
- Clinical trials
- Access to care
02 · Program
Hard questions worth two days
02
Uveal melanoma therapeutics
Adjuvant and neoadjuvant strategies at a moment of genuine therapeutic change.
03
New FDA approvals
What has cleared, what it means at the chair and what it costs the patient.
04
Intraocular lymphoma
Diagnosis, systemic coordination and the cases that stay difficult.
03 · Faculty
Led from Byers Eye Institute
Program Director
Prithvi Mruthyunjaya, MD, MHS
Director of Ocular Oncology and member of the Vitreoretinal Surgery Service
Innovate Series Committee
Diana V. Do, MD
Byers Eye Institute, Palo Alto, CA
Quan Dong Nguyen, MD, MSc
Byers Eye Institute, Palo Alto, CA
Stephen Smith, MD
Byers Eye Institute, Palo Alto, CA
04 · Venue
Paul Brest Hall, Stanford
Paul Brest Hall
Stanford University
555 Salvatierra Walk
Stanford, CA 94305
Stanford University
555 Salvatierra Walk
Stanford, CA 94305
Friday and Saturday on campus. Abstract presentations run across both days.
Under the objective
The work of the meeting, up close
05 · Support
Grant support
Educational grant
Aura Biosciences has provided an educational grant.
Credit
Credit statement
No CME credit
This meeting does not offer CME credit.